I experience more PVC's; tinnitus (auditory); cardiac-related events; heart-racing; dizziness; orthostatic hypotension; dose 1 30Sep2021; dose 2 30Nov2021; This is a spontaneous report received from a contactable reporter(s) (Nurse). The reporter is the patient.  An adult patient received BNT162b2 (BNT162B2), on 30Nov2021 at 11:00 as dose 2, single (Lot number: FJ1620) at the age of 41 years intramuscular for covid-19 immunisation. The patient's relevant medical history included: "Folic acid supplement" (unspecified if ongoing); "Preventive" (unspecified if ongoing); "Good health and preventive" (unspecified if ongoing), notes: Good health and preventive; "Eye health and preventive" (unspecified if ongoing), notes: Eye health and preventive. Concomitant medication(s) included: L-METHYLFOLATE oral taken for vitamin supplementation (ongoing); CALCIUM MAGNESIUM ZINC [CALCIUM;MAGNESIUM;ZINC] oral taken for prophylaxis (ongoing); FISH OIL oral taken for prophylaxis (ongoing); PRESERVISION AREDS 2 oral taken for prophylaxis (ongoing); VITAMIN B12 [VITAMIN B12 NOS] oral taken for prophylaxis (ongoing); VITAMIN D3 oral taken for prophylaxis (ongoing); PROBIOTICS NOS oral taken for prophylaxis (ongoing). Vaccination history included: BNT162b2 (Dose Number: 01, Time: 12:45, Anatomical site of injection: Left deltoid/arm, Route of administration: Intramuscular, Batch/lot number: Pfizer EW0167), administration date: 30Sep2021, when the patient was 41-year-old, for COVID-19 Immunization, reaction(s): "Premature ventricular contractions", "Pericarditis", "Myocarditis", "chest pain". The following information was reported: INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (non-serious) with onset 30Nov2021 at 11:00, outcome "unknown", described as "dose 1 30Sep2021; dose 2 30Nov2021"; VENTRICULAR EXTRASYSTOLES (non-serious), outcome "unknown", described as "I experience more PVC's"; TINNITUS (non-serious), outcome "unknown", described as "tinnitus (auditory)"; CARDIAC DISORDER (non-serious), outcome "unknown", described as "cardiac-related events"; PALPITATIONS (non-serious), outcome "unknown", described as "heart-racing"; DIZZINESS (non-serious), outcome "unknown"; ORTHOSTATIC HYPOTENSION (non-serious), outcome "unknown". Relevant laboratory tests and procedures are available in the appropriate section.  Additional information: Additional information: Prior vaccination was reported as none. I received the first dose of COVID-19 vaccine and soon after began experiencing cardiac symptoms. After some time, I consulted with my primary care physician who ordered some routine blood work and two other tests (EKG and Echo). It was determined that the results were at within normal limits, so I pursued the second dose of the COVID-19 vaccine. It has been some months since and as of today I can report that I experience more PVCs tinnitus (auditory) and more cardiac related events (including heart racing and dizziness (orthostatic hypotension) than I did before receive the two COVID-19 vaccines. I have had over 10 days of chest pain and an increase in PVCs after receiving the first dose of Pfizer COVID-19 vaccination. I reached out to my healthcare provider before pursuing the 2nd dose, to advise me. He consulted with a cardiologist, and it is recommended that I seek further testing (EKG, echocardiogram) before receiving 2nd dose.